Company: OSRH
Filing Date: 2025-01-31
Form Type: 424B3
Source: 0001213900-25-008874
Chunk: 306

Company: OSR Holdings, Inc.
Filing Date: 2025-01-31
Form: 424B3
Chunk 306
---
 factors pertaining to the Business Combination as generally supporting the decision to enter into the Business Combination Agreement and the transactions contemplated thereby, including but not limited to, the following material factors: • Strong management team The consolidated management team from the holding company to each subsidiary consists of experienced professionals coming from scientific, entrepreneurial, capital market and regulatory backgrounds who, as a team, are well positioned to create interdisciplinary synergies. • Strong business model The Hub -and -Spokebiotech model is one of the highest -performingbusiness models in the global biopharmaceutical market over the past decade. Due to its risk/return profile as a portfolio of experimental drug R&D assets, it is increasingly being perceived as a business model which provides competitive edges especially in terms of raising new capital. • Multiple channels to access capital across the U.S., South Korea and in Europe In addition to the U.S. capital market which OSR Holdings expects to be able to access post -closingof the Business Combination, OSR Holdings’ management team mainly consists of the financial market professionals in South Korea whose access to institutional investors and investment banks are highly likely to add value to the Combined Company’s fundraising and IR activities in Korea. Also, Vaximm as a Swiss company has a management team whose presence, network and track records of fundraising for a diverse group of biotech firms based in Switzerland and France could benefit the post -closingCompany’s capital raising efforts going forward. • Significant value creation and growth opportunities OSR Holdings’ subsidiaries are developing drug candidates in some of the areas with the highest unmet medical needs such as glioblastoma (GBM), hepatocellular cancer (HCC) and disease modifying treatment for osteoarthritis (“DMOADs”). The officers and directors of BLAC have substantial experience in evaluating the operating and financial merits of companies from a wide range of industries and concluded that their experience and background enabled them to make the necessary analyses and determinations regarding the Business Combination. In the course of its deliberations, the BLAC M&A Committee also considered a variety of uncertainties, risks and other potentially negative factors relevant to the Business Combination, including the following which are based upon our diligence: •BLAC’s public stockholders will hold a minority share position in the post -combinationcompany; •BLAC stockholders may object to and challenge the Business Combination and take actions that may prevent or delay the consummation of the Business Combination, including to vote down the proposals at the special meeting or exercise their redemption rights; •the potential for diversion of management